How to appeal a Humana ms treatments denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for ms treatments

Cited policy: Humana Medicare Advantage and Commercial Pharmacy Coverage Policies for MS DMTs

Confirmed MS diagnosis by neurologist. Documented disease activity. Step therapy varies. Part B vs Part D distinction important for infusions (Ocrevus/Tysabri/Briumvi often Part B). TOUCH REMS for Tysabri.

How Humana denies ms treatments — and how to counter it

Where Humana pushes back: 1) Part D step therapy not satisfied; 2) Site-of-care restrictions (forcing infusion to home/non-hospital setting); 3) HSCT for MS denied as experimental; 4) Age-related concerns for high-efficacy in older Medicare population.

Counter-arguments that hold up: Site-of-care: cite patient-specific clinical factors requiring monitored infusion (history of reactions, comorbidities). AAN 2018 supports individualized DMT selection regardless of age when active disease documented. For HSCT: MIST + HALT-MS + EBMT 2020 — Humana's investigational classification is outdated. Reference DISCO-MS (Corboy, Lancet Neurol 2023) for any age-based discontinuation argument: discontinuation in stable older patients reasonable, but ACTIVE disease at any age warrants treatment.

What Humana typically denies for ms treatments

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For ms treatments, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the ms treatments treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Ocrevus
• Kesimpta
• Briumvi
• Tysabri
• Lemtrada
• S1P modulator

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.